All In Biotech

NDA 020049 · Takeda Pharms USA

Pentasa

Mesalamine · Oral · Aminosalicylate

Priority review

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

May 10, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

188

77 Phase 3, 14 recruiting

FAERS reports

43,912

36,874 serious, 2,603 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

PENTASA is indicated for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis in adult patients. PENTASA is an aminosalicylate indicated for the induction of remission and for the treatment of mildly to moderately active ulcerative colitis in adult patients. ( 1 )

Mechanism: The mechanism of action of mesalamine is not fully understood, but it appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids) and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids), is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 10, 1993 Original approval · Type 3 - New Dosage Form · priority review Review
2 products under this application
  • PENTASA · MESALAMINE 250MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • PENTASA · MESALAMINE 500MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.

All 188 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use8,661
  • drug ineffective5,980
  • colitis ulcerative5,816
  • condition aggravated4,320
  • diarrhoea3,945
  • abdominal pain3,208
  • fatigue3,198
  • haematochezia3,172
  • nausea2,748
  • headache2,623
  • pyrexia2,548
  • weight decreased2,528

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004339
2005372
2006354
2007453
2008754
2009588
2010688
20111,353
20121,565
20131,133
20141,274
20151,355
20161,237
20171,047
20181,385
20191,647
20202,189
20213,496
20225,122
20235,137
20244,860
20254,753
20262,809

Recalls

1 FDA enforcement reports for this application.

  • Dec 2, 2016 · Class III · Terminated

    Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 16, 2026

    Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81). Product is anticipated to be available until December 31, 2027

  • To Be Discontinued · updated Sep 16, 2026

    Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12). Product is anticipated to be available until December 31, 2027

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pentasa (Mesalamine)

2024 spending

$30.0M

Beneficiaries

5,070

22,117 claims

Per beneficiary

$5,923

$5.03 per unit

View as table
YearSpending
2020$83,459,058
2021$77,151,842
2022$52,064,617
2023$34,395,079
2024$30,028,073

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 303 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.